[Stockholm, Sweden, September 27, 2005.] Swedish drug development company OxyPharma will participate in the US-bound Swedish Biotech Mission, organized by Invest in Sweden Agency (ISA). Existing and potential partners, members of the press and potential investors are welcome to meet OxyPharma in Raleigh, N.C., San Diego, CA., and San Francisco, CA., October 21st- 26th.

OxyPharma’s is one of approx. 20 Swedish companies participating in a series of Bio-Business events in Raleigh, N.C., San Diego, CA., and San Francisco, CA., organized by ISA, Invest in Sweden Agency. The events will include morning seminars, lunch buffets and B2B meetings in each location.

OxyPharma is a Swedish drug development company focusing on RA and MS drugs. The latest developments in OxyPharma include the recently announced successful completion of preclinical safety evaluation and toxicity studies on the company’s patented RA candidate drug Rob 803 (announced in late August 2005). Earlier this year (in April), OxyPharma selected Rob 895 as its candidate drug for the treatment of multiple sclerosis (MS).

The aim of the Swedish Biotech Mission is to introduce US biotech, pharmaceutical and venture capital companies to what may be Europe’s best kept biotech secret – Sweden is ranked among the top four biotech nations in Europe, with around 200 very active companies and world-class academic research institutions such as the Karolinska Institute (home of the Nobel Prize in Medicine and Physiology).
Members of the press are cordially invited to meet OxyPharma’s CEO Ulf Björklund in any of the locations: Raleigh, N.C., Oct 20-21, San Diego, CA., Oct 22-24, and/or San Francisco, CA., Oct 25-26. Please contact Mr. Björklund directly to set up meetings (phone number +46 8 726 17 02 or +46 70 667 04 40, email adress ulf.bjorklund@oxypharma.com).